Cargando…

Natural Products in Renal-Associated Drug Discovery

The global increase in the incidence of kidney failure constitutes a major public health problem. Kidney disease is classified into acute and chronic: acute kidney injury (AKI) is associated with an abrupt decline in kidney function and chronic kidney disease (CKD) with chronic renal failure for mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wruck, Wasco, Genfi, Afua Kobi Ampem, Adjaye, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451693/
https://www.ncbi.nlm.nih.gov/pubmed/37627594
http://dx.doi.org/10.3390/antiox12081599
_version_ 1785095478908551168
author Wruck, Wasco
Genfi, Afua Kobi Ampem
Adjaye, James
author_facet Wruck, Wasco
Genfi, Afua Kobi Ampem
Adjaye, James
author_sort Wruck, Wasco
collection PubMed
description The global increase in the incidence of kidney failure constitutes a major public health problem. Kidney disease is classified into acute and chronic: acute kidney injury (AKI) is associated with an abrupt decline in kidney function and chronic kidney disease (CKD) with chronic renal failure for more than three months. Although both kidney syndromes are multifactorial, inflammation and oxidative stress play major roles in the diversity of processes leading to these kidney malfunctions. Here, we reviewed various publications on medicinal plants with antioxidant and anti-inflammatory properties with the potential to treat and manage kidney-associated diseases in rodent models. Additionally, we conducted a meta-analysis to identify gene signatures and associated biological processes perturbed in human and mouse cells treated with antioxidants such as epigallocatechin gallate (EGCG), the active ingredient in green tea, and the mushroom Ganoderma lucidum (GL) and in kidney disease rodent models. We identified EGCG- and GL-regulated gene signatures linked to metabolism; inflammation (NRG1, E2F1, NFKB1 and JUN); ion signalling; transport; renal processes (SLC12A1 and LOX) and VEGF, ERBB and BDNF signalling. Medicinal plant extracts are proving to be effective for the prevention, management and treatment of kidney-associated diseases; however, more detailed characterisations of their targets are needed to enable more trust in their application in the management of kidney-associated diseases.
format Online
Article
Text
id pubmed-10451693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104516932023-08-26 Natural Products in Renal-Associated Drug Discovery Wruck, Wasco Genfi, Afua Kobi Ampem Adjaye, James Antioxidants (Basel) Review The global increase in the incidence of kidney failure constitutes a major public health problem. Kidney disease is classified into acute and chronic: acute kidney injury (AKI) is associated with an abrupt decline in kidney function and chronic kidney disease (CKD) with chronic renal failure for more than three months. Although both kidney syndromes are multifactorial, inflammation and oxidative stress play major roles in the diversity of processes leading to these kidney malfunctions. Here, we reviewed various publications on medicinal plants with antioxidant and anti-inflammatory properties with the potential to treat and manage kidney-associated diseases in rodent models. Additionally, we conducted a meta-analysis to identify gene signatures and associated biological processes perturbed in human and mouse cells treated with antioxidants such as epigallocatechin gallate (EGCG), the active ingredient in green tea, and the mushroom Ganoderma lucidum (GL) and in kidney disease rodent models. We identified EGCG- and GL-regulated gene signatures linked to metabolism; inflammation (NRG1, E2F1, NFKB1 and JUN); ion signalling; transport; renal processes (SLC12A1 and LOX) and VEGF, ERBB and BDNF signalling. Medicinal plant extracts are proving to be effective for the prevention, management and treatment of kidney-associated diseases; however, more detailed characterisations of their targets are needed to enable more trust in their application in the management of kidney-associated diseases. MDPI 2023-08-11 /pmc/articles/PMC10451693/ /pubmed/37627594 http://dx.doi.org/10.3390/antiox12081599 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wruck, Wasco
Genfi, Afua Kobi Ampem
Adjaye, James
Natural Products in Renal-Associated Drug Discovery
title Natural Products in Renal-Associated Drug Discovery
title_full Natural Products in Renal-Associated Drug Discovery
title_fullStr Natural Products in Renal-Associated Drug Discovery
title_full_unstemmed Natural Products in Renal-Associated Drug Discovery
title_short Natural Products in Renal-Associated Drug Discovery
title_sort natural products in renal-associated drug discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451693/
https://www.ncbi.nlm.nih.gov/pubmed/37627594
http://dx.doi.org/10.3390/antiox12081599
work_keys_str_mv AT wruckwasco naturalproductsinrenalassociateddrugdiscovery
AT genfiafuakobiampem naturalproductsinrenalassociateddrugdiscovery
AT adjayejames naturalproductsinrenalassociateddrugdiscovery